GlassScriptPhysician profile
Timothy T Tran
NPI 1316164171
$3,627.29
in general payments reported to CMS, 2019-2025
27 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $135 · 2021: $114 · 2022: $763 · 2023: $704 · 2024: $843 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $59.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.33 |
| Education | $59.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.54 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Pfizer INC. | $457.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $343.41 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $308.70 | 2019-2025 | |
| Janssen Biotech, INC. | $253.87 | 2019-2025 | Tremfya |
| Celgene Corporation | $193.38 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $173.29 | 2024 | Rezdiffra |
| Merck Sharp & Dohme LLC | $167.29 | 2022-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $157.67 | 2022-2023 | Entyvio |
| Qol Medical, LLC | $136.35 | 2022-2025 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.46 | 2022 | |
| Janssen Scientific Affairs, LLC | $106.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $77.79 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $52.50 | 2023-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $36.32 | 2024-2025 | Iqirvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.17 | 2021 | |
| Fresenius Kabi USA, LLC | $28.00 | 2023 | |
| Genzyme Corporation | $27.45 | 2025 | |
| Siemens Medical Solutions USA, INC. | $26.99 | 2022 | |
| Shionogi INC | $26.19 | 2019-2020 | |
| Novo Nordisk INC | $22.99 | 2025 | Wegovy |
| Sandoz INC. | $22.45 | 2023 | Hyrimoz |
| Allergan, INC. | $22.21 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.40 | 2025 | Dupixent |
| Celltrion USA INC. | $19.56 | 2024 | Vegzelma |
| Redhill Biopharma INC. | $18.08 | 2020 | |
| Genentech USA, INC. | $17.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.